Monte Rosa Therapeutics, Inc. GLUE 深 沪
等待开盘 05-19 09:30:00 美东时间
18.01
-0.140
-0.77%
华盛通- 最 高18.57
- 今 开18.33
- 成交量 64.21万股
- 最 低 17.67
- 昨 收 18.15
- 总市值 15.21亿
- 52周最高 25.77
- 市盈率 静 --
- 换手率 0.76%
- 52周最低 3.90
- 委 比 77.92%
- 总股本 8447.94万
- 历史最高 45.56
- 量 比 0.85
- 振 幅 4.96%
- 历史最低 2.44
- 每 手 1
- 风险率 6.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $30 to $31.
05-12 03:10
Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 178.95 percent decrease over earnings of $0.57 per
05-07 21:32
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
05-07 01:35
Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified Solid Tumors At AACR Annual Meeting 2026
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced
04-20 19:09
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.33) by 65.17 percent. This is a 339.13 percent decrease over earnings of $0.23 per
03-17 20:10
Monte Rosa Enters Into Supply Agreement With Johnson & Johnson To Evaluate MRT-2359 In Combination With ERLEADA For Treatment Of Patients With mCRPC With AR Mutations In Planned Phase 2 Study Expected To Initiate In Q3 Of 2026
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated
03-16 19:06
Monte Rosa Highlights Updated Phase 1/2 Data Showing 67% Overall RECIST Disease Control And Tumor Reductions In Heavily Pretreated mCRPC
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2
02-24 20:19
